萬邦德(002082.SZ)子公司藥品擬中標國家藥品集中採購
格隆匯8月20日丨萬邦德(002082.SZ)公佈,2020年8月20日,公司全資子公司萬邦德製藥集團有限公司(以下簡稱“萬邦德製藥”)參加了聯合採購辦公室組織的第三批全國藥品集中採購的投標工作。萬邦德製藥已獲得國家藥品監督管理局仿製藥質量和療效一致性評價的仿製藥品氯氮平片擬中標本次集中採購。
本次中標將有利於萬邦德製藥充分發揮氯氮平原料藥及製劑一體化生產優勢,萬邦德製藥已經做好充分的生產準備,可以確保本標期內的原料藥和片劑市場供應;有利於氯氮平片在通過一致性評價後,快速擴大其國內市場的銷售覆蓋面,提高市場佔有率和品牌影響力,對公司未來經營業績產生積極的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.